Search

Peginterferon lambda-1a

Peginterferon lambda-1a is under investigation in clinical trial NCT01754974 (Safety and Efficacy Study of Peginterferon Lambda-1a vs. … Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C).

OPC-51803

It is a V(2)-selective agonist that produces a significant antidiuretic action after single and multiple oral dosing in AVP-deficient and normal AVP states. … It is useful therapeutic drug in the treatment of hypothalamic diabetes insipidus, nocturnal enuresis, and some kinds of urinary incontinence.

Prolectin-M

Prolectin-M is a (1-6)-alpha-D-mannopyranose[L31338] and acts as an antagonist of galectin. … [L31343] It is being investigated in the clinical trial NCT04512027 (Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support. (Prolectin-M)).

CX516

Cediranib

The novel indole-ether quinazoline Cediranib is a highly potent (IC₅₀ < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. … It is being developed clinically as a once-daily oral therapy for the treatment of cancer.

Parecoxib

A letter of non-approval for parecoxib was issued by the FDA in 2005. … Parecoxib is a water-soluble and injectable prodrug of valdecoxib. It is marketed as Dynastat in the European Union.

Glypromate

In December 2008, the company discontinued further development of the drug after it failed to show an observable effect. … the potential treatment of neurodegenerative diseases by IV infusion.

AT-7519

AT7519 is a selective inhibitor of certain Cyclin Dependent Kinases (CDKs) leading to tumour regression. It is developed by Astex for the treatment of solid tumours and haematological malignancies.

Firocoxib

Firocoxib is a cycooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug. It currently approved for veterinary use in dogs and horses under the brand names Equioxx and Previcox. … Firocoxib is not intended or approved for use in human medicine.

EVT-101